Society guideline links: Cancer of the kidney and ureters

Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

International

●International Kidney Cancer Coalition (IKCC): An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma (2022)

●World Health Organization (WHO): Classification of tumours – Urinary and male genital tumours, 5th edition (2022)

•WHO: Classification of tumours of the urinary system and male genital organs – Part A: Renal, penile, and testicular tumours (2022)

●Society for Immunotherapy of Cancer (SITC): Clinical practice guideline on immunotherapy for the treatment of urothelial cancer (2021)

●SITC: Consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC) (2019)

Canada

●Canadian Urological Association (CUA): Guideline for management of small renal masses (2022)

●Clinical consensus statement on genetic risk assessment for hereditary renal cell carcinoma (2021)

●Kidney Cancer Research Network of Canada (KCRNC): Consensus update for the management of advanced kidney cancer (2021)

●CUA/Genitourinary Medical Oncologists of Canada (GUMOC): Consensus statement for the management of unresectable locally advanced and metastatic urothelial carcinoma (2019)

●KCRNC: Consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma (2019)

●KCRNC: Consensus statement on the role of renal mass biopsy in the management of kidney cancer (2019)

●CUA: Guideline for followup of patients after treatment of non-metastatic renal cell carcinoma (2018)

●KCRNC: Consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma – A comprehensive analysis of the literature and meta-analysis of randomized controlled trials (2018)

●Cancer Care Ontario (CCO): Updated guideline for the use of targeted therapies in patients with inoperable locally advanced or metastatic renal cell cancer (2017)

●CUA: Guideline on the management of cystic renal lesions (2017)

●CCO: Focal tumour ablation for renal cell carcinoma (2016)

●KCRNC: Consensus statement for structured assessment and followup for patients with hereditary kidney tumour syndromes (2016)

●KCRNC: Canadian Kidney Cancer Forum consensus on the surgical management of renal cell carcinoma (2014)

●CCO: Interferon-alfa in the treatment of patients with inoperable locally advanced or metastatic renal cell cancer (2013)

●KCRNC: Canadian guideline on genetic screening for hereditary renal cell cancers (2013)

●CUA: Guidelines for the management of the incidentally discovered adrenal mass (2011)

United States

●National Cancer Institute (NCI): Renal cell cancer treatment – Health professional version

●American College of Radiology (ACR): ACR Appropriateness Criteria on post-treatment follow-up and active surveillance of clinically localized renal cell cancer (2021)

●American Urological Association (AUA): Guideline on renal mass and localized renal cancer – Evaluation, management, and follow-up (2021)

●Clinical consensus statement on genetic risk assessment for hereditary renal cell carcinoma (2021)

●ACR: ACR Appropriateness Criteria on indeterminate renal mass (2020)

●Society of Interventional Radiology (SIR): Position statement on the role of percutaneous ablation in renal cell carcinoma (2020)

●American Society of Clinical Oncology (ASCO): Clinical practice guideline for the management of small renal masses (2017)

●ACR: ACR Appropriateness Criteria on renal cell carcinoma staging (2015)

Europe

●European Association of Urology (EAU): Guidelines on renal cell carcinoma, update (2022)

●EAU: Guidelines on upper urinary tract urothelial carcinoma, update (2022)

●European Society for Medical Oncology (ESMO): Clinical practice guideline on the use of immunotherapy in early stage and advanced renal cell carcinoma, update (2021)

•ESMO: Clinical practice guidelines on renal cell carcinoma (2019, updated 2020)

●Cardiovascular and Interventional Radiological Society of Europe (CIRSE): Guidelines on percutaneous ablation of small renal cell carcinoma (2016)

United Kingdom

●Royal College of Radiologists (RCR): Recommendations for cross-sectional imaging in cancer management, 2nd edition − Bladder cancer and urothelial tumours (2014)

●RCR: Recommendations for cross-sectional imaging in cancer management, 2nd edition − Renal and adrenal tumours (2014)

●National Institute for Health and Care Excellence (NICE): Interventional procedures guidance for irreversible electroporation for treating renal cancer (2013)

●NICE: Interventional procedures guidance for laparoscopic cryotherapy for renal cancer (2011)

●NICE: Interventional procedures guidance on percutaneous cryotherapy for renal cancer (2011)

●NICE: Interventional procedures guidance on percutaneous radiofrequency ablation for renal cancer (2010)

Japan

●[In English] Pan-Asian adapted European Society for Medical Oncology (ESMO) clinical practice guidelines for the diagnosis, treatment, and follow-up of patients with renal cell carcinoma (2021)

●[In Japanese] Japanese Urological Association (JUA): Guidelines for clinical practice of renal cancer (2017)

●[In English] JUA: Evidenced-based clinical practice guideline for upper tract urothelial carcinoma (summary), 2014 edition (published 2015)

●[In Japanese] JUA: Guidelines for diagnosis and treatment of renal pelvis and ureter cancer (2014)